TIRF REMS Access Program Home

What is the TIRF REMS Access Program?

The Transmucosal Immediate Release Fentanyl (TIRF) Risk Evaluation and Mitigation Strategy (REMS) program is an FDA-required program designed to ensure informed risk-benefit decisions before initiating treatment, and while patients are treated, to ensure appropriate use of TIRF medicines. The purpose of the TIRF REMS Access program is to mitigate the risk of misuse, abuse, addiction, overdose and serious complications due to medication errors with the use of TIRF medicines.

You must enroll in the TIRF REMS Access program to prescribe, dispense, or distribute TIRF medicines.

If you have never enrolled in a REMS program for a product that is covered under the TIRF REMS Access program, click Create My Account.

Click here for a list of Products Covered under the TIRF REMS Access program

Important Safety Information (ISI) is included on the bottom of the Home Page. To reduce the space and image distortion, ISI is not shown as part of Home Page in this document.